Immunic, Inc (IMUX)

Trade IMUX now with
3/16/2022 6:32:56 AM Immunic Announces Promotion Of Glenn Whaley To CFO
2/24/2022 7:11:13 AM Immunic FY Net Loss $92.9 Mln Or $3.93/basic Shr Vs. Loss $44 Mln Or $2.81/basic Shr Prior Year
2/18/2022 6:39:36 AM Immunic Announces Phase 2 CALDOSE-1 Trial Of Vidofludimus Calcium In Ulcerative Colitis
12/16/2021 5:09:52 PM Wedbush Reiterates Immunic, Inc (IMUX) At Outperform With $61 Price Target
12/14/2021 6:36:15 AM Immunic : Data Show IMU-935 Maintains Normal Thymocyte Maturation In Relevant Acute And Chronic Mouse Models
11/4/2021 6:40:55 AM Immunic Q3 Net Loss $19.3 Mln Or $0.76/shr Vs. Loss $12.9 Mln Or $0.70/shr Prior Year
10/28/2021 6:38:38 AM Immunic Completes Enrollment Of Phase 2 CALDOSE-1 Trial Of IMU-838 In Moderate-to-Severe Ulcerative Colitis
10/27/2021 6:39:34 AM Immunic Says First Psoriasis Patient Enrolled In Ongoing Phase 1 Trial Of IMU-935
10/14/2021 6:32:12 AM Immunic Appoints Patrick Walsh As Chief Business Officer
8/6/2021 6:41:31 AM Amended: Immunic Q2 Loss/shr $0.82 Vs. Loss/shr $0.90 Last Year
7/15/2021 9:23:38 AM Immunic Prices Underwritten Public Offering Of 4.50 Mln Shares At $10/shr
7/14/2021 4:09:13 PM Immunic Announces Proposed Public Offering Of Common Stock
7/1/2021 6:32:35 AM Immunic Unveils FDA Clearance To Begin IMU-838 Phase 3 ENSURE Studies In RRMS
4/15/2021 6:41:21 AM Immunic Says Interim Data From Cohort 2 Of Phase 2 EMPhASIS Trial Of IMU-838 In Relapsing-remitting Multiple Sclerosis
3/31/2021 8:53:06 AM Immunic, 4SC Sign Deal Regarding Settlement Of Royalty Obligations For Immunic's Lead Program, IMU-838
2/26/2021 7:11:53 AM Immunic FY Loss Per Share $2.81 Vs Loss $4.52 Last Year